2.2% Pharmacy Cost Reduction for 2017March 6th, 2018 | Clinical Connections
We are pleased to report that for our Excellus population last year, we realized a 2.2% reduction in global spend on pharmaceuticals for patients under the AHP umbrella. This is a prime example of our combined ongoing efforts translating into improved performance and cost savings. With the escalating prices of prescription drugs, and high cost agents coming to the market, effecting a net savings in pharmacy costs is a tremendous achievement. Through your efforts with initiatives such as the clobetasol use reduction, highlighted in the Triple Aim Reports over the last year, we were able to achieve this reduction. In addition, with our newly developing AHP P&T Committee, we look forward to identifying further opportunities for other savings for our patients and our network in the pharmaceutical realm.